July 1, 2024
Evariste is proud to join NVIDIA Inception, leveraging NVIDIA's cutting-edge technology to support innovation in drug discovery.
Evariste has recently been accepted into NVIDIA's Inception program, an initiative that supports innovative startups revolutionizing industries with technological advancements.
With NVIDIA's support, we anticipate significant enhancements to Frobenius, our AI-enabled drug discovery platform that identifies novel blockbuster synthetic lethal targets and develops best-in-class small molecule therapeutics.
As a member of NVIDIA Inception, Evariste will gain access to NVIDIA's state-of-the-art technology, expert guidance, and a network of forward-thinking teams. We are particularly enthusiastic about the opportunities this partnership provides for our exploratory research projects, which require substantial computational resources. NVIDIA's technical assistance and cloud compute credits will be instrumental in advancing this research.
This milestone coincides with a pivotal moment for Evariste. We have received promising preclinical data for our lead PKMYT1 program and are making swift progress with our early-stage programs, validating the capabilities of Frobenius.
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
Stay updated with Evariste's blogposts
.png)
